Loading clinical trials...

Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of SGB-3908 After a Single Administration in Healthy Subjects and Mildly Hypertensive Subjects

NCT06501586•Suzhou Sanegene Bio Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects. The study will be a single ascending dose (SAD) phase.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Has body mass index (BMI) ≥18 and ≤30 kg/m\^2 and has bodyweight ≥ 50 kg;
•Has Systolic blood pressure (SBP) ≥100 mmHg and ≤150 mmHg and diastolic blood pressure (DBP) ≥65 mmHg and ≤95 mmHg at screening;

Exclusion Criteria

•Has mental illness, liver and kidney disease, gastrointestinal disease, nervous system disease, or other related systemic diseases that affect the trial;
•Has a history of hospitalization or other clinically significant diseases within 1 month before screening, major surgery within 6 months before screening, or other unstable conditions judged by the investigator;
•Has a history of orthostatic hypotension or syncope;
•Patients with clinically significant abnormalities confirmed by physical examination, 12-lead electrocardiogram, laboratory tests, etc., or those who meet any of the following conditions during screening need to be excluded:
•1. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin higher than 1.5× upper limit of normal (ULN)
•2. Serum creatinine (Cr) higher than ULN
•3. Serum potassium higher than 5 mmol/L
•4. QT/QTc interval prolongation during screening (QTcF\>450 ms)

Locations (1)

Peking University Third Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

July 31, 2024

Primary Completion Date

April 7, 2025

Completion Date

December 15, 2025

Last Updated

February 10, 2026

Enrollment

ACTUAL participants

Conditions

Hypertension,Essential

Interventions

SGB-3908

DRUG

SGB-3908-Matching placebo

OTHER

The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature

NCT05067998

Anxiety Disorders and SymptomsFibromyalgia+3 more

View study

RECRUITINGPHASE3

Phase III Study to Evaluate the Efficacy and Safety of AD-209

NCT06348576

Hypertension,Essential

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects

Inclusion Criteria

Exclusion Criteria

The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Genetic of Response to Acute Saline Load Test in Hypertension (Naload)

Long-term Use of CCB and Breast Cancer Risk

Implementing Hypertension Screening Guidelines in Primary Care

The TARGET BP OFF-MED Trial